<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245362</url>
  </required_header>
  <id_info>
    <org_study_id>P-0011</org_study_id>
    <nct_id>NCT00245362</nct_id>
  </id_info>
  <brief_title>A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cell Genesys</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cell Genesys</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of CG8020 and CG2505.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate clinical and laboratory safety of CG 8020 and CG 2505 and to evaluate the
      efficacy of CG 8020 and CG 2505 as measured by clinical benefit response, progression-free
      survival, survival and CA 19-9 serum marker levels in chemotherapy naive or experienced
      patients with nonresectable or metastatic adenocarcinoma of the pancreas
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date>June 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy measured by clinical benefit response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survivial</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <enrollment>50</enrollment>
  <condition>Metastatic Pancreatic Cancer</condition>
  <condition>Nonresectable Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CG 8020 and CG 2505</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic or cytologic diagnosis of nonresectable or metastatic pancreatic
             adenocarcinoma

          -  Chemotherapy na√Øve or chemotherapy experienced pancreatic cancer

        Exclusion Criteria:

          -  Prior cancer vaccines or gene therapy

          -  History of clinically significant autoimmune disease (eg, systemic lupus
             erythematosus, sarcoidosis, rheumatoid arthritis, glomerulonephritis, or vasculitis)

          -  History of another malignancy in the past five years, except adequately treated
             non-melanomatous skin cancer or superficial bladder cancer or carcinoma-in-situ of the
             cervix, unless approved by the Medical Monitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2005</study_first_submitted>
  <study_first_submitted_qc>October 27, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2005</study_first_posted>
  <last_update_submitted>October 27, 2005</last_update_submitted>
  <last_update_submitted_qc>October 27, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2005</last_update_posted>
  <keyword>cancer vaccine</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>metastatic pancreatic cancer</keyword>
  <keyword>unresectable pancreatic cancer</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

